Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Toxicokinetics of adefovir dipivoxil and remofovir in 28-day toxicity studies

  • At: 2004 FIP Congress in New Orleans (USA)
  • Type: Poster
  • By: XU, Christine (Valeant Pharmaceuticals International, Drug Development, Costa Mesa, United States of America)
  • Co-author(s): Vitarella (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
    Lin (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
    Yeh (Valeant Pharmaceuticals International, COSTA MESA, United States of America)
  • Abstract:

    Aim: Adefovir dipivoxil and remofovir are oral prodrugs of the PMEA that indicated for the treatment of chronic hepatitis B. This study was to compare the toxicokinetics of adefovir dipivoxil and remofovir as well as PMEA following repeated doses of adefovir dipivoxil or remofovir for 28 days in rats. Methods: Animals received daily oral..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses